Alenka Boban Blagaic

Alenka Boban Blagaic

Auto-generated profile, based on publicly available information

Alenka Boban Blagaic

University of Zagreb School of Medicine Department of Pharmacology , Zagreb Croatia

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 January 2005 in Burns
Verified
Journal Article
Closed access
MBMario Bilić
Mario Bilić
ZBZ. Bumber
Z. Bumber
ABA. Boban Blagaic
A. Boban Blagaic
LBL. Batelja
L. Batelja
SSSven Seiwerth
Sven Seiwerth
PSPredrag Sikiric
Predrag Sikiric

4 August 2020 in Current Pharmaceutical Design
Verified
Journal Article
Closed access
PDF file
PSPredrag Sikiric
Predrag Sikiric
DDDomagoj Drmic
Domagoj Drmic
MSMarko Sever
Marko Sever
RKRobert Klicek
Robert Klicek
ABAlenka Boban Blagaic
Alenka Boban Blagaic
SSSven Seiwerth
Sven Seiwerth
This review is focused on the healing of fistulas and stable gastric pentadecapeptide BPC 157. Assuming that the healing of the various wounds is essential also for the gastrointestinal fistulas healing, the healing effect on fistulas in rats, consistently noted with the stable gastric pentadecapeptide BPC 157, may raise several interesting possibilities. BPC 157 is originally an anti-ulcer agent, native to and stable in human gastric juice (for more than 24 h). Likely, it is a novel mediator of Robert’s cytoprotection maintaining gastrointestinal mucosal integrity. Namely, it is effective in the whole gastrointestinal tract, and heals various wounds (i.e., skin, muscle, tendon, ligament, bone; ulcers in the entire gastrointestinal tract; corneal ulcer); LD1 is not achieved. It is used in ulcerative colitis clinical trials, and now in multiple sclerosis, and addressed in several reviews. Therefore, it is not surprising that BPC 157 has documented consistent healing of the various gastrointestinal fistulas, external (esophagocutaneous, gastrocutaneous, duodenocutaneous, colocutaneous) and internal (colovesical, rectovaginal). Taking fistulas as a pathological connection, this rescue is verified with the beneficial effects in rats with the various gastrointestinal anastomoses, esophagogastric, jejunoileal, colo-colonic, ileoileal, esophagojejunal, esophagoduodenal, and gastrojejunal. This beneficial effect occurs equally when the gastrointestinal anastomoses are impaired with the application of NSAIDs, cysteamine, large bowel resection, as well as concomitant esophageal, gastric, and duodenal lesions and/or ulcerative colitis presentation, short bowel syndrome progression, liver and brain disturbances presentation. Particular aspects of the BPC 157 healing of the fistulas are especially emphasized.

1 December 2025 in Acta Pharmaceutica
Verified
Journal Article
Open access
PDF file
PTPetra Turčić
Petra Turčić
RMRoko Martinić
Roko Martinić
NŠNikola Štambuk
Nikola Štambuk
TWTin Weitner
Tin Weitner
MMMirna Momcilovic
Mirna Momcilovic
RSRanko Stojković
Ranko Stojković
L -Met-enkephalin is a neuropeptide known to exert protective effects in various experimental models of autoimmune and inflammatory diseases. These effects are mediated through opioid receptors and can be abolished by the opioid receptor antagonist naltrexone. Investigation of peptide enantiomerism and the incorporation of d-amino acids are crucial for designing novel peptides with altered structural and biological properties compared with their native l-forms. Since no data are currently available on the properties or biological activity of the d-Met-enkephalin enantiomer, we evaluated its hepatoprotective potential in a mouse model of acetaminophen-induced hepatotoxicity. Male CBA mice were treated with d-Met-enkephalin, and hepatoprotection was assessed by measuring plasma alanine aminotransferase (ALT) and aspartate amino-transferase (AST) activities, along with histological liver necrosis scores. The peptide’s secondary structure and antisense peptide binding were analysed using circular dichroism and fluorescence spectroscopy, respectively. d -Met-enkephalin demonstrated dose-dependent hepatoprotective effects within the range of 0.5–20 mg kg–1, with maximal protection observed at 5 mg kg –1 , a dose comparable to that of the l-enantiomer (7.5 mg kg –1 ). This preservation of biological activity may be attributed to the presence of the achiral amino acid glycine at positions 2 and 3, which maintains the functional conformation of the d-enantiomer. The role of opioid receptor involvement was further examined through direct receptor blockade using naltrexone and indirect inhibition with the antisense peptide IPPKY.

21 January 2022 in Frontiers in Pharmacology
Verified
Journal Article
Open access
MTMarijan Tepes
Marijan Tepes
SGSlaven Gojkovic
Slaven Gojkovic
IKIvan Krezic
Ivan Krezic
HZHelena Zizek
Helena Zizek
Hrvoje VranesHrvoje Vranes
Hrvoje Vranes
PSPredrag Sikiric
Predrag Sikiric
Corrigendum: Stable Gastric Pentadecapeptide BPC 157 Therapy for Primary Abdominal Compartment Syndrome in Rats